Towards a Therapy for Geographic Atrophy: A Patient's Experience

Overview

Journal Patient Prefer Adherence

Date 2023 Feb 9

PMID 36756537

Authors

Jamie Enoch

Arevik Ghulakhszian

Mandeep Sekhon

David P Crabb

Deanna J Taylor

Christiana Dinah

Affiliations

Soon will be listed here.

Abstract

Purpose: Geographic atrophy (GA) is the advanced form of the non-neovascular (dry) type of age-related macular degeneration. Presently, GA cannot be treated. However, new therapies administered by intravitreal injection are in late-stage development. These can slow down, but do not stop or reverse, GA progression. The acceptability of these emerging therapies to people with GA is currently unknown. The present case study explores the perspectives of a person living with GA who took part in the terminated Phase 3 clinical trial of Lampalizumab, a candidate intravitreal treatment for GA. We explored this patient's perspective on the retrospective acceptability of regular Lampalizumab injections, and the prospective acceptability of future intravitreal therapies for GA.

Patients And Methods: A 78-year-old woman living in the UK was recruited as part of a mixed-methods pilot study and interviewed by telephone, regarding: her experience of the Lampalizumab trial injections; and her thoughts regarding emerging intravitreal therapies for GA. The Framework Method was used for initial inductive analysis of the interview transcript. Subsequently, deductive analysis was undertaken, informed by the Theoretical Framework of Acceptability (TFA).

Results: For this participant, intravitreal injections in the Lampalizumab trial were acceptable, although streamlining processes within the clinic would have improved the patient experience. Regarding prospective acceptability of new intravitreal therapies, the participant considered a delay in progression of GA a valuable goal. Potential discomfort, anxiety and inconvenience associated with regular intravitreal injections would be acceptable in the context of preserving her vision for as long as possible.

Conclusion: Analysis of one participant's experience demonstrates the value of exploring GA patients' unique views on the acceptability of new intravitreal treatments. Larger prospective studies will provide more insight that help to optimise treatment design and delivery, thereby maximising likelihood of adherence and persistence when these therapies eventually arrive in clinic.

Citing Articles

Proliferative Sickle Cell Retinopathy: A Patient and a Physician's Perspective on Quality of Life and Quality of Eye Care.

Taylor C, Awadzi R, Enoch J, Dinah C Ophthalmol Ther. 2024; 13(4):851-860.

PMID: 38345709 PMC: 10912386. DOI: 10.1007/s40123-024-00893-3.

References

Rosenfeld P, Brown D, Heier J, Boyer D, Kaiser P, Chung C . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-31. DOI: 10.1056/NEJMoa054481. View

Joko T, Nagai Y, Mori R, Tanaka K, Oshima Y, Hikichi Y . Patient Preferences for Anti-Vascular Endothelial Growth Factor Treatment for Wet Age-Related Macular Degeneration in Japan: A Discrete Choice Experiment. Patient Prefer Adherence. 2020; 14:553-567. PMC: 7082633. DOI: 10.2147/PPA.S228890. View

Chakravarthy U, Bailey C, Johnston R, McKibbin M, Khan R, Mahmood S . Characterizing Disease Burden and Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration. Ophthalmology. 2018; 125(6):842-849. DOI: 10.1016/j.ophtha.2017.11.036. View

Ferris 3rd F, Wilkinson C, Bird A, Chakravarthy U, Chew E, Csaky K . Clinical classification of age-related macular degeneration. Ophthalmology. 2013; 120(4):844-51. PMC: 11551519. DOI: 10.1016/j.ophtha.2012.10.036. View

Kovacs K, Ciulla T, Kiss S . Advancements in ocular gene therapy delivery: vectors and subretinal, intravitreal, and suprachoroidal techniques. Expert Opin Biol Ther. 2022; 22(9):1193-1208. DOI: 10.1080/14712598.2022.2121646. View

Gale N, Heath G, Cameron E, Rashid S, Redwood S . Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013; 13:117. PMC: 3848812. DOI: 10.1186/1471-2288-13-117. View

Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C, Rees G . Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med. 2017; 23(2):127-140. DOI: 10.1080/13548506.2016.1274040. View

Banes M, Culham L, Bunce C, Xing W, Viswanathan A, Garway-Heath D . Agreement between optometrists and ophthalmologists on clinical management decisions for patients with glaucoma. Br J Ophthalmol. 2006; 90(5):579-85. PMC: 1857057. DOI: 10.1136/bjo.2005.082388. View

Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J . A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015; 16:495. PMC: 4632358. DOI: 10.1186/s13063-015-1023-4. View

10.

Holz F, Sadda S, Busbee B, Chew E, Mitchell P, Tufail A . Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials. JAMA Ophthalmol. 2018; 136(6):666-677. PMC: 6145777. DOI: 10.1001/jamaophthalmol.2018.1544. View

11.

Heier J, Brown D, Chong V, Korobelnik J, Kaiser P, Nguyen Q . Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012; 119(12):2537-48. DOI: 10.1016/j.ophtha.2012.09.006. View

12.

Sekhon M, Cartwright M, Francis J . Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res. 2017; 17(1):88. PMC: 5267473. DOI: 10.1186/s12913-017-2031-8. View

13.

Liao D, Grossi F, El Mehdi D, Gerber M, Brown D, Heier J . Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology. 2019; 127(2):186-195. DOI: 10.1016/j.ophtha.2019.07.011. View

14.

Jaffe G, Westby K, Csaky K, Mones J, Pearlman J, Patel S . C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2020; 128(4):576-586. DOI: 10.1016/j.ophtha.2020.08.027. View

15.

Ziemssen F, Feltgen N, Holz F, Guthoff R, Ringwald A, Bertelmann T . Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials. BMC Ophthalmol. 2017; 17(1):7. PMC: 5244516. DOI: 10.1186/s12886-017-0401-y. View

16.

McCormick J . How Should a Research Ethicist Combat False Beliefs and Therapeutic Misconception Risk in Biomedical Research?. AMA J Ethics. 2018; 20(11):E1100-1106. DOI: 10.1001/amajethics.2018.1100. View

17.

Enoch J, Ghulakhszian A, Crabb D, Dinah C, Taylor D . Acceptability of intravitreal injections in geographic atrophy: protocol for a mixed-methods pilot study. BMJ Open. 2021; 11(4):e049495. PMC: 8074551. DOI: 10.1136/bmjopen-2021-049495. View

18.

Elliott D, Husbands S, Hamdy F, Holmberg L, Donovan J . Understanding and Improving Recruitment to Randomised Controlled Trials: Qualitative Research Approaches. Eur Urol. 2017; 72(5):789-798. DOI: 10.1016/j.eururo.2017.04.036. View

19.

Dinah C, Enoch J, Ghulakhszian A, Taylor D, Crabb D . Intravitreal treatment for geographic atrophy: coming soon to a patient near you?. Eye (Lond). 2021; 36(5):1121-1123. PMC: 9046256. DOI: 10.1038/s41433-021-01591-1. View

20.

Finger R, Daien V, Eldem B, Talks J, Korobelnik J, Mitchell P . Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems. BMC Ophthalmol. 2020; 20(1):294. PMC: 7368708. DOI: 10.1186/s12886-020-01554-2. View